References
- Ezzati M, Henley S J, Lopez AD, Thun MJ. Role of smoking in global and regional cancer epidemiology: current patterns and data needs. Int. J. Cancer116, 963–971 (2005).
- Coleman M, Forman D, Bryant H et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet377(9760), 99–101 (2011).
- Manser RL, Irving LB, Byrnes G, Abramson MJ, Stone CA, Campbell DA. Screening for lung cancer: a systematic review and meta-analysis of controlled trials. Thorax58(9), 784–789 (2003).
- Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS. Survival of patients with stage I lung cancer detected on CT screening. N. Engl. J. Med.355(17), 1763–1771 (2006).
- National Lung Screening Trial Research Team. The National Lung Screening Trial: overview and study design. Radiology258(1), 243–253 (2010).
- Hocking WG, Hu P, Oken MM et al. Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial. J. Natl Cancer Inst.102(10), 722–731 (2010).
- Wisnivesky JP, Mushlin AI, Sicherman N, Henschke C. The cost–effectiveness of low-dose CT screening for lung cancer: preliminary results of baseline screening. Chest124(2), 614–621 (2003).
- Manser R. Cost–effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting. Lung Cancer48(2), 171–185 (2005).
- Marcus PM, Bergstrahl EJ, Zweig MH, Harris A, Offord KP, Fontana RS. Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis. J. Natl Cancer Inst.98, 748–756 (2006).
- Silvestri GA, Nietert PJ, Zoller J et al. Attitudes towards screening for lung cancer among smokers and their non-smoking counterparts. Thorax62, 126–130 (2007).
- Whynes DK. Could CT screening for lung cancer ever be cost effective in the United Kingdom? Cost Eff. Resour. Alloc.6, 5 (2008).
- Van Iersel CA, de Koning HJ, Draisma G et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch–Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int. J. Cancer120, 868–874 (2007).
- Baldwin DR, Duffy SW, Wald NJ, Page R, Hansell DM, Field JK. UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer. Thorax66, 308–313 (2011).
- Cassidy A, Myles J, van-Tongeren M et al. The LLP risk model: an individual risk prediction model for lung cancer. Br. J. Cancer98, 270–276 (2008).
- Rudd MF, Webb EL, Matakidou A et al.; GELCAPS Consortium. Variants in the GH–IGF axis confer susceptibility to lung cancer. Genome Res.16(6), 693–701 (2006).
- Tufman A, Huber RM. Biological markers in lung cancer: a clinician’s perspective. Cancer Biomark.6(3–4), 123–135 (2010).
- Harris RP, Helfand M, Woolf SH et al. Current methods of the US Preventive Services Task Force: a review of the process. Am. J. Prev. Med.20(Suppl. 3), 21–35 (2001).